Clinical Trial Update: Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 study assessing the immunogenicity of a 2-dose regimen of the 9-valent HPV vaccine in children aged 4 to 8 years; the trial status is ACTIVE_NO…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Boston Medical Center | Conditions: Human Papilloma Virus | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING